Tag: rare skin disease gene therapy clinical trials 2024
2024 U.S. Epidermolysis Bullosa Gene Therapy Guide: FDA Approval, Cost, Insurance Coverage, Healing Rates & Clinical Trials
Per October 2024 U.S. FDA, American Academy of Dermatology, and National Organization for Rare Disorders data, this 2024 epidermolysis bullosa (EB) gene therapy buying guide breaks down verified coverage, cost, and healing rates for U.S. patients. We compare premium FDA-approved Vyjuvek and Zevaskyn vs unregulated counterfeit overseas gene therapy models, with peer-reviewed data showing 67%